ERBB2 and neoplasm: No significant beneficial effect of pertuzumab was seen in the patients with a non-HER2-type tumor overall (aOR 1.84, 95% CI 0.51–6.62, p = 0.35, n = 95; Fig. 4a) or within the Luminal-type subgroup (aOR 1.72, 95% CI 0.44–6.73, n = 85).